Filing Details
- Accession Number:
- 0001104659-23-086416
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-08-01 17:00:14
- Reporting Period:
- 2023-08-01
- Accepted Time:
- 2023-08-01 17:00:14
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1621227 | Adaptimmune Therapeutics Plc | ADAP | Biological Products, (No Disgnostic Substances) (2836) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1784487 | John Lunger | C/O Adaptimmune Therapeutics Plc 60 Jubilee Avenue, Milton Park Abingdon X0 OX14 4RX | Chief Patient Supply Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| American Depositary Shares Representing Ordinary Shares | Disposition | 2023-08-01 | 3,096 | $0.91 | 4,718 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Footnotes
- Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on August 1, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.
- The price reported in Column 4 is the sale price per ADS.
- The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 83,637 ADSs and RSU-style options and other options covering an aggregate of 7,864,224 ordinary shares of the Issuer.
Billionaire Hedge Funds
